Refractory Osteosarcoma Clinical Trials

6 recruiting

Refractory Osteosarcoma Trials at a Glance

7 actively recruiting trials for refractory osteosarcoma are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Atlanta, Boston, and Houston. Lead sponsors running refractory osteosarcoma studies include Emory University, Children's Oncology Group, and Fred Hutchinson Cancer Center.

Browse refractory osteosarcoma trials by phase

Treatments under study

About Refractory Osteosarcoma Clinical Trials

Looking for clinical trials for Refractory Osteosarcoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Refractory Osteosarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Refractory Osteosarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Relapsed / Refractory Osteosarcoma
Lantheus Medical Imaging55 enrolled2 locationsNCT07357519
Recruiting
Phase 2

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Metastatic OsteosarcomaRecurrent OsteosarcomaRefractory Osteosarcoma+2 more
M.D. Anderson Cancer Center40 enrolled2 locationsNCT05019703
Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Refractory OsteosarcomaOsteosarcoma in ChildrenOsteosarcoma Recurrent+1 more
Emory University24 enrolled1 locationNCT07144254
Recruiting
Phase 1Phase 2

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1

Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial

Recurrent OsteosarcomaRefractory OsteosarcomaAdvanced Osteosarcoma
Fred Hutchinson Cancer Center30 enrolled1 locationNCT07227571
Recruiting
Phase 1

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

NeuroblastomaRefractory OsteosarcomaRefractory Neuroblastoma+2 more
Emory University24 enrolled1 locationNCT05400603